Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Arrowhead delivers in the lung
Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.
AACR 2023 – more hope for Moderna’s neoantigen immunotherapy
After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.
Spotlight – Vertex flexes its dealmaking muscle
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
